1-3 of 3
Sophie Ifrah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Timothy Hughes, Jorge E. Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Shruti Kapoor, Sophie Ifrah, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 6767–6768.
https://doi.org/10.1182/blood-2022-162249
Published: 2022
Journal Articles

Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase

Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Shruti Kapoor, Sophie Ifrah, Timothy P. Hughes
Journal: Blood
Blood (2021) 138 (Supplement 1): 1478.
https://doi.org/10.1182/blood-2021-151239
Published: 2021
Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3835.
https://doi.org/10.1182/blood-2019-128043
Published: 2019